Jung-Mao Hsu

Title: Innovations by Inventor Jung-Mao Hsu in Cancer Therapy

Introduction: Jung-Mao Hsu, a prominent inventor based in Houston, TX, has made significant contributions to the field of cancer therapy through his innovative research and patented inventions. With two patents to his name, he has focused on developing biomarkers that assist in predicting resistance to specific cancer treatments, particularly cetuximab.

Latest Patents: Among Jung-Mao Hsu's notable patents is the invention titled "Detection of arginine methylation of EGFR for prediction of resistance to therapy." This groundbreaking work provides biomarkers, such as the methylation of R198 or R200 of EGFR and the presence of an arginine at position 497 of EGFR. These biomarkers are crucial for predicting resistance to cetuximab therapy. Furthermore, his invention outlines methods for selecting patients for combination therapy with cetuximab and PRMT inhibitors, enhancing treatment efficacy.

Career Highlights: Jung-Mao Hsu is affiliated with the University of Texas System, where he continues to engage in revolutionary research. His work aims not only to improve cancer treatment outcomes but also to bring forth innovative solutions that can change the landscape of patient care.

Collaborations: Throughout his career, Jung-Mao Hsu has collaborated with esteemed colleagues, including Mien-Chie Hung and Hsin-Wei Liao. These collaborations highlight the interdisciplinary approach taken by his team in advancing cancer research and developing effective therapies.

Conclusion: With his innovative contributions, Jung-Mao Hsu stands out as a significant figure in the field of cancer therapy. His inventions, through their predictive capabilities regarding resistance to treatment, hold the potential to improve the lives of many patients. As research continues to evolve, Jung-Mao Hsu's work will undoubtedly play a crucial role in shaping the future of cancer treatments.